Patents by Inventor Bernd Buettelmann

Bernd Buettelmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM
    Publication number: 20220411415
    Abstract: Compounds having the formula (I) wherein R1, R2, R3, R4, R5, R6, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: July 16, 2021
    Publication date: December 29, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bernd BUETTELMANN, Giuseppe Cecere, Bernhard Fasching, Katrin Groebke Zbinden, Maria-Clemencia Hernandez, Henner Knust, Andreas Koblet, Emmanuel Pinard, Andrew Thomas
  • Isoxazolyl ether derivatives as GABA?5 PAM
    Patent number: 11091471
    Abstract: Compounds having the formula (I) wherein R1, R2, R3, R4, R5, R6, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: August 17, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Giuseppe Cecere, Bernhard Fasching, Katrin Groebke Zbinden, Maria-Clemencia Hernandez, Henner Knust, Andreas Koblet, Emmanuel Pinard, Andrew Thomas
  • Spiroindolinones as DDR1 inhibitors
    Patent number: 10618897
    Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: April 14, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Buelent Kocer, Bernd Kuhn, Marco Prunotto, Hans Richter, Martin Ritter
  • Triaza-spirodecanones as DDR1 inhibitors
    Patent number: 10435407
    Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein L and R1 to R5 are as described herein, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: October 8, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Buelent Kocer, Bernd Kuhn, Marco Prunotto, Hans Richter, Martin Ritter, Markus Rudolph, Alexander Lee Satz
  • ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM
    Publication number: 20190300516
    Abstract: Compounds having the formula (I) wherein R1, R2, R3, R4, R5, R6, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: June 5, 2019
    Publication date: October 3, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bernd BUETTELMANN, Giuseppe CECERE, Bernhard FASCHING, Katrin GROEBKE ZBINDEN, Maria-Clemencia HERNANDEZ, Henner KNUST, Andreas KOBLET, Emmanuel PINARD, Andrew THOMAS
  • TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS
    Publication number: 20190169189
    Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein L and R1 to R5 are as described herein, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
    Type: Application
    Filed: February 4, 2019
    Publication date: June 6, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: BERND BUETTELMANN, BUELENT KOCER, BERND KUHN, MARCO PRUNOTTO, HANS RICHTER, MARTIN RITTER, MARKUS RUDOLPH, ALEXANDER LEE SATZ
  • Triaza-spirodecanones as DDR1 inhibitors
    Patent number: 10239876
    Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein L and R1 to R5 are as described herein, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: March 26, 2019
    Assignee: Hoffman La-Roche Inc.
    Inventors: Bernd Buettelmann, Buelent Kocer, Bernd Kuhn, Marco Prunotto, Hans Richter, Martin Ritter, Markus Rudolph, Alexander Lee Satz
  • SPIROINDOLINONES AS DDR1 INHIBITORS
    Publication number: 20190071444
    Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
    Type: Application
    Filed: August 7, 2018
    Publication date: March 7, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Buelent Kocer, Bernd Kuhn, Marco Prunotto, Hans Richter, Martin Ritter
  • TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS
    Publication number: 20180148450
    Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein L and R1 to R5 are as described herein, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
    Type: Application
    Filed: December 21, 2017
    Publication date: May 31, 2018
    Applicant: Hoffmann La-Roche Inc.
    Inventors: Bernd BUETTELMANN, Buelent KOCER, Bernd KUHN, Marco PRUNOTTO, Hans RICHTER, Martin RITTER, Markus RUDOLPH, Alexander Lee SATZ
  • Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors
    Patent number: 9708340
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, W, A and B are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: July 18, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Simona M. Ceccarelli, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Hans Richter
  • COMT inhibitors
    Patent number: 9656971
    Abstract: The present invention relates to compounds of formula wherein the substituents are described in claim 1 and to the pharmaceutically acceptable salts thereof. These compounds inhibit the enzyme catechol-O-methyltransferase (COMT). The compounds may be used for the treatment of Parkinson's disease, depression, cognitive impairment and motor symptoms, resistant depression, cognitive impairment, mood and negative symptoms of schizophrenia.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: May 23, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Caterina Bissantz, René Bonnafous, Bernd Buettelmann, Roland Jakob-Roetne, Christian Lerner, Markus Rudolph
  • Bicyclic thiophenylamide compounds
    Patent number: 9604977
    Abstract: Compounds having the formula (I) wherein R1, R2, R3, R4, R5, R6, R7, A, E and n are as described herein, compositions including the compounds and methods of using the compounds as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors for the treatment or prophylaxis of type 2 diabetes, atherosclerosis, chronic kidney diseases, non-alcoholic steatohepatitis and cancer.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: March 28, 2017
    Assignee: Hoffman-La Roche Inc.
    Inventors: Bernd Buettelmann, Simona M. Ceccarelli, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Hans Richter
  • Bicyclicpyridine derivatives
    Patent number: 9562052
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, A1, A2, A3, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: February 7, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Hans Richter
  • UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS
    Publication number: 20160185795
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, W, A and B are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: September 16, 2015
    Publication date: June 30, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: BERND BUETTELMANN, SIMONA M. CECCARELLI, AURELIA CONTE, HOLGER KUEHNE, BERND KUHN, WERNER NEIDHART, ULRIKE OBST SANDER, HANS RICHTER
  • Non-annulated thiophenylamides
    Patent number: 9353102
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, A, E and n are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: May 31, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Simona M. Ceccarelli, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Hans Richter
  • Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors
    Patent number: 9278918
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, W, A and B are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: March 8, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Simona M. Ceccarelli, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Hans Richter
  • UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS
    Publication number: 20160002152
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, W, A and B are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: September 17, 2015
    Publication date: January 7, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: BERND BUETTELMANN, SIMONA M. CECCARELLI, AURELIA CONTE, HOLGER KUEHNE, BERND KUHN, WERNER NEIDHART, ULRIKE OBST SANDER, HANS RICHTER
  • COMT INHIBITORS
    Publication number: 20160002177
    Abstract: The present invention relates to compounds of formula wherein the substituents are described in claim 1 and to the pharmaceutically acceptable salts thereof. These compounds inhibit the enzyme catechol-O-methyltransferase (COMT). The compounds may be used for the treatment of Parkinson's disease, depression, cognitive impairment and motor symptoms, resistant depression, cognitive impairment, mood and negative symptoms of schizophrenia.
    Type: Application
    Filed: June 26, 2015
    Publication date: January 7, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Caterina BISSANTZ, René Bonnafous, Bernd Buettelmann, Roland Jakob-Roetne, Christian Lerner, Markus Rudolph
  • NEW BICYCLICPYRIDINE DERIVATIVES
    Publication number: 20150368256
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, A1, A2, A3, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: February 20, 2015
    Publication date: December 24, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Bernd Buettelmann, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Hans Richter
  • Isoxazolo-pyridine derivatives
    Patent number: 9073908
    Abstract: The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R1 to R6 are as described herein. The compounds are active on the GABA A ?5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: July 7, 2015
    Assignee: ROCHE PALO ALTO LLC
    Inventors: Bernd Buettelmann, Roland Jakob-Roetne, Henner Knust, Matthew C. Lucas, Andrew Thomas